Healthcare provider profile · identity verified

Jasjit Singh, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SHREVEPORT, LA · NPI 1265466197

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jasjit Singh, MD received $169,239.38 in general payments during 2025 across 297 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 35.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 21 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Auvelity, Ingrezza, Invega Sustenna, Lybalvi, Trintellix.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Auvelity by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Invega Sustenna by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ingrezza by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Austedo Xr by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$169,239.38

297 reported records · 16 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$60,196.41	35.6%	90	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$49,309.76	29.1%	59	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$38,362.24	22.7%	51	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$20,317.60	12.0%	45	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$201.99	0.1%	12	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$153.67	0.1%	4	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$134.94	0.1%	7	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$113.85	0.1%	6	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$87.29	0.1%	4	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$76.41	0.1%	4	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$70.82	0.0%	4	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$61.22	0.0%	3	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$51.51	0.0%	2	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$44.72	0.0%	2	2025
Corium, LLC	Unresolved — no canonical attribution shown	$37.58	0.0%	3	2025
Sage Therapeutics, LLC	Unresolved — no canonical attribution shown	$19.37	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$89,232.00	34
Honoraria	$45,225.00	17
Travel and Lodging	$17,023.82	62
Consulting Fee	$13,375.00	6
Food and Beverage	$4,348.71	173
Education	$34.85	5

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$60,196.41	90	2025
Source payment records 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.44 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,160.00 · Open Payments source 2025-02-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.00 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.77 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,780.00 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $172.20 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5.43 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.66 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,160.00 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.40 · Open Payments source 2025-08-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.09 · Open Payments source 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $79.60 · Open Payments source 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $214.04 · Open Payments source 2025-08-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $823.37 · Open Payments source 2025-08-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.07 · Open Payments source 2025-08-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-08-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.55 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6,660.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.40 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $60.75 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $38.67 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.81 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.20 · Open Payments source 2025-08-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.57 · Open Payments source 2025-08-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.95 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $95.20 · Open Payments source 2025-09-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.54 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.60 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.17 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.11 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.07 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.84 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.65 · Open Payments source 2025-09-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.11 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.84 · Open Payments source 2025-10-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-10-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.35 · Open Payments source 2025-10-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.08 · Open Payments source 2025-10-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $114.80 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $230.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.30 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $460.97 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.36 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.07 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $30.11 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,179.44 · Open Payments source 2025-10-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $546.37 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $20.48 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.60 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $840.84 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6,105.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-10-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.23 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.57 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.40 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.22 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $39.30 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $25.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.00 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $38.95 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.40 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $106.45 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.60 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.20 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.70 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $40.22 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,665.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.11 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.52 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,665.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.63 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$49,309.76	59	2025
Source payment records 2025-03-01 · Axsome Therapeutics, Inc. · $20.05 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $34.24 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $49.45 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $74.19 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $24.73 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $24.73 · Open Payments source 2025-03-01 · Axsome Therapeutics, Inc. · $776.47 · Open Payments source 2025-03-31 · Axsome Therapeutics, Inc. · $29.44 · Open Payments source 2025-03-31 · Axsome Therapeutics, Inc. · $21.00 · Open Payments source 2025-03-31 · Axsome Therapeutics, Inc. · $13.10 · Open Payments source 2025-04-02 · Axsome Therapeutics, Inc. · $9.88 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $14.82 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $3.82 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $17.39 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $16.96 · Open Payments source 2025-04-07 · Axsome Therapeutics, Inc. · $205.80 · Open Payments source 2025-04-08 · Axsome Therapeutics, Inc. · $7,425.00 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $22.89 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $16.37 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $5.42 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $2,006.55 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-04-29 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-04-30 · Axsome Therapeutics, Inc. · $8.44 · Open Payments source 2025-05-02 · Axsome Therapeutics, Inc. · $21.53 · Open Payments source 2025-05-02 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-05-02 · Axsome Therapeutics, Inc. · $15.55 · Open Payments source 2025-05-02 · Axsome Therapeutics, Inc. · $60.20 · Open Payments source 2025-05-05 · Axsome Therapeutics, Inc. · $17.16 · Open Payments source 2025-05-05 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-05-05 · Axsome Therapeutics, Inc. · $6.40 · Open Payments source 2025-05-05 · Axsome Therapeutics, Inc. · $113.40 · Open Payments source 2025-05-08 · Axsome Therapeutics, Inc. · $1,350.00 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $10.17 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-05-28 · Axsome Therapeutics, Inc. · $21.00 · Open Payments source 2025-05-30 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-05-30 · Axsome Therapeutics, Inc. · $8.40 · Open Payments source 2025-06-05 · Axsome Therapeutics, Inc. · $8.56 · Open Payments source 2025-07-09 · Axsome Therapeutics, Inc. · $22.41 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $15.86 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $7.55 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $21.61 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $18.04 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $154.70 · Open Payments source 2025-10-20 · Axsome Therapeutics, Inc. · $1,012.50 · Open Payments source 2025-10-27 · Axsome Therapeutics, Inc. · $25.30 · Open Payments source 2025-10-27 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-10-27 · Axsome Therapeutics, Inc. · $11.90 · Open Payments source 2025-10-27 · Axsome Therapeutics, Inc. · $112.00 · Open Payments source 2025-10-31 · Axsome Therapeutics, Inc. · $8.88 · Open Payments source 2025-10-31 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-10-31 · Axsome Therapeutics, Inc. · $8.40 · Open Payments source 2025-12-08 · Axsome Therapeutics, Inc. · $1,012.50 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$31,347.24	48	2025
Source payment records 2025-01-22 · E.R. Squibb & Sons, L.L.C. · $125.50 · Open Payments source 2025-02-20 · E.R. Squibb & Sons, L.L.C. · $4.37 · Open Payments source 2025-04-14 · E.R. Squibb & Sons, L.L.C. · $19.61 · Open Payments source 2025-04-18 · E.R. Squibb & Sons, L.L.C. · $1,840.00 · Open Payments source 2025-04-18 · E.R. Squibb & Sons, L.L.C. · $21.00 · Open Payments source 2025-04-29 · E.R. Squibb & Sons, L.L.C. · $1,610.00 · Open Payments source 2025-05-12 · E.R. Squibb & Sons, L.L.C. · $18.23 · Open Payments source 2025-06-16 · E.R. Squibb & Sons, L.L.C. · $2,760.00 · Open Payments source 2025-06-24 · E.R. Squibb & Sons, L.L.C. · $20.09 · Open Payments source 2025-06-24 · E.R. Squibb & Sons, L.L.C. · $157.50 · Open Payments source 2025-08-20 · E.R. Squibb & Sons, L.L.C. · $7.89 · Open Payments source 2025-09-03 · E.R. Squibb & Sons, L.L.C. · $23.23 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $848.24 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-10-24 · E.R. Squibb & Sons, L.L.C. · $1,196.00 · Open Payments source 2025-10-24 · E.R. Squibb & Sons, L.L.C. · $2,760.00 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $73.31 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $131.68 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $170.10 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $46.23 · Open Payments source 2025-11-10 · E.R. Squibb & Sons, L.L.C. · $9.09 · Open Payments source 2025-11-12 · E.R. Squibb & Sons, L.L.C. · $9.09 · Open Payments source 2025-11-12 · E.R. Squibb & Sons, L.L.C. · $9.43 · Open Payments source 2025-11-17 · E.R. Squibb & Sons, L.L.C. · $934.92 · Open Payments source 2025-11-17 · E.R. Squibb & Sons, L.L.C. · $212.81 · Open Payments source 2025-11-17 · E.R. Squibb & Sons, L.L.C. · $64.13 · Open Payments source 2025-11-18 · E.R. Squibb & Sons, L.L.C. · $1,841.09 · Open Payments source 2025-11-18 · E.R. Squibb & Sons, L.L.C. · $814.44 · Open Payments source 2025-11-19 · E.R. Squibb & Sons, L.L.C. · $9.09 · Open Payments source 2025-11-25 · E.R. Squibb & Sons, L.L.C. · $1,840.00 · Open Payments source 2025-11-26 · E.R. Squibb & Sons, L.L.C. · $14.00 · Open Payments source 2025-12-04 · E.R. Squibb & Sons, L.L.C. · $1,196.00 · Open Payments source 2025-12-04 · E.R. Squibb & Sons, L.L.C. · $3,680.00 · Open Payments source 2025-12-04 · E.R. Squibb & Sons, L.L.C. · $1,196.00 · Open Payments source 2025-12-04 · E.R. Squibb & Sons, L.L.C. · $1,564.00 · Open Payments source 2025-12-08 · E.R. Squibb & Sons, L.L.C. · $19.90 · Open Payments source 2025-12-09 · E.R. Squibb & Sons, L.L.C. · $1,945.83 · Open Payments source 2025-12-15 · E.R. Squibb & Sons, L.L.C. · $1,380.00 · Open Payments source 2025-12-23 · E.R. Squibb & Sons, L.L.C. · $1,840.00 · Open Payments source 2025-12-30 · E.R. Squibb & Sons, L.L.C. · $33.57 · Open Payments source 2025-12-30 · E.R. Squibb & Sons, L.L.C. · $114.80 · Open Payments source 2025-12-30 · E.R. Squibb & Sons, L.L.C. · $98.30 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$20,317.60	45	2025
Source payment records 2025-01-09 · Alkermes, Inc. · $19.90 · Open Payments source 2025-01-22 · Alkermes, Inc. · $14.00 · Open Payments source 2025-01-30 · Alkermes, Inc. · $56.00 · Open Payments source 2025-02-07 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-02-19 · Alkermes, Inc. · $19.88 · Open Payments source 2025-02-27 · Alkermes, Inc. · $130.00 · Open Payments source 2025-03-04 · Alkermes, Inc. · $105.53 · Open Payments source 2025-03-06 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-03-07 · Alkermes, Inc. · $14.00 · Open Payments source 2025-03-18 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-03-20 · Alkermes, Inc. · $154.00 · Open Payments source 2025-03-20 · Alkermes, Inc. · $30.61 · Open Payments source 2025-03-21 · Alkermes, Inc. · $15.63 · Open Payments source 2025-03-24 · Alkermes, Inc. · $2.60 · Open Payments source 2025-03-24 · Alkermes, Inc. · $17.55 · Open Payments source 2025-04-01 · Alkermes, Inc. · $129.37 · Open Payments source 2025-04-02 · Alkermes, Inc. · $6.79 · Open Payments source 2025-04-10 · Alkermes, Inc. · $23.97 · Open Payments source 2025-04-11 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-04-11 · Alkermes, Inc. · $16.80 · Open Payments source 2025-04-22 · Alkermes, Inc. · $3.79 · Open Payments source 2025-05-01 · Alkermes, Inc. · $3.79 · Open Payments source 2025-05-01 · Alkermes, Inc. · $5.95 · Open Payments source 2025-05-13 · Alkermes, Inc. · $960.00 · Open Payments source 2025-05-14 · Alkermes, Inc. · $9.18 · Open Payments source 2025-05-21 · Alkermes, Inc. · $19.78 · Open Payments source 2025-05-21 · Alkermes, Inc. · $2.95 · Open Payments source 2025-05-27 · Alkermes, Inc. · $29.84 · Open Payments source 2025-05-27 · Alkermes, Inc. · $14.97 · Open Payments source 2025-06-06 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-06-06 · Alkermes, Inc. · $14.66 · Open Payments source 2025-06-06 · Alkermes, Inc. · $94.50 · Open Payments source 2025-06-06 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-06-18 · Alkermes, Inc. · $52.38 · Open Payments source 2025-06-18 · Alkermes, Inc. · $95.20 · Open Payments source 2025-06-18 · Alkermes, Inc. · $17.81 · Open Payments source 2025-06-18 · Alkermes, Inc. · $2.55 · Open Payments source 2025-07-16 · Alkermes, Inc. · $7.02 · Open Payments source 2025-07-31 · Alkermes, Inc. · $20.90 · Open Payments source 2025-07-31 · Alkermes, Inc. · $1.49 · Open Payments source 2025-08-06 · Alkermes, Inc. · $17.52 · Open Payments source 2025-08-11 · Alkermes, Inc. · $17.83 · Open Payments source 2025-08-11 · Alkermes, Inc. · $2.87 · Open Payments source 2025-08-15 · Alkermes, Inc. · $960.00 · Open Payments source 2025-09-03 · Alkermes, Inc. · $5.99 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$238.16	20	2025
Source payment records 2025-01-09 · Alkermes, Inc. · $19.90 · Open Payments source 2025-02-19 · Alkermes, Inc. · $19.88 · Open Payments source 2025-03-21 · Alkermes, Inc. · $15.63 · Open Payments source 2025-03-24 · Alkermes, Inc. · $2.60 · Open Payments source 2025-03-24 · Alkermes, Inc. · $17.55 · Open Payments source 2025-04-02 · Alkermes, Inc. · $6.79 · Open Payments source 2025-04-10 · Alkermes, Inc. · $23.97 · Open Payments source 2025-05-01 · Alkermes, Inc. · $5.95 · Open Payments source 2025-05-14 · Alkermes, Inc. · $9.18 · Open Payments source 2025-05-21 · Alkermes, Inc. · $19.78 · Open Payments source 2025-05-21 · Alkermes, Inc. · $2.95 · Open Payments source 2025-06-18 · Alkermes, Inc. · $17.81 · Open Payments source 2025-06-18 · Alkermes, Inc. · $2.55 · Open Payments source 2025-07-16 · Alkermes, Inc. · $7.02 · Open Payments source 2025-07-31 · Alkermes, Inc. · $20.90 · Open Payments source 2025-07-31 · Alkermes, Inc. · $1.49 · Open Payments source 2025-08-06 · Alkermes, Inc. · $17.52 · Open Payments source 2025-08-11 · Alkermes, Inc. · $17.83 · Open Payments source 2025-08-11 · Alkermes, Inc. · $2.87 · Open Payments source 2025-09-03 · Alkermes, Inc. · $5.99 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$201.99	12	2025
Source payment records 2025-02-03 · Neurocrine BioSciences, Inc. · $24.62 · Open Payments source 2025-02-03 · Neurocrine BioSciences, Inc. · $2.00 · Open Payments source 2025-03-03 · Neurocrine BioSciences, Inc. · $25.02 · Open Payments source 2025-05-05 · Neurocrine BioSciences, Inc. · $20.80 · Open Payments source 2025-07-07 · Neurocrine BioSciences, Inc. · $19.84 · Open Payments source 2025-07-09 · Neurocrine BioSciences, Inc. · $14.36 · Open Payments source 2025-07-09 · Neurocrine BioSciences, Inc. · $3.10 · Open Payments source 2025-07-23 · Neurocrine BioSciences, Inc. · $32.75 · Open Payments source 2025-07-31 · Neurocrine BioSciences, Inc. · $13.54 · Open Payments source 2025-09-17 · Neurocrine BioSciences, Inc. · $26.33 · Open Payments source 2025-09-17 · Neurocrine BioSciences, Inc. · $2.55 · Open Payments source 2025-12-02 · Neurocrine BioSciences, Inc. · $17.08 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$134.94	7	2025
Source payment records 2025-01-22 · Collegium Pharmaceutical, Inc. · $19.86 · Open Payments source 2025-02-27 · Collegium Pharmaceutical, Inc. · $21.55 · Open Payments source 2025-05-22 · Collegium Pharmaceutical, Inc. · $19.82 · Open Payments source 2025-08-27 · Collegium Pharmaceutical, Inc. · $18.49 · Open Payments source 2025-10-22 · Collegium Pharmaceutical, Inc. · $12.12 · Open Payments source 2025-11-13 · Collegium Pharmaceutical, Inc. · $20.98 · Open Payments source 2025-12-17 · Collegium Pharmaceutical, Inc. · $22.12 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$113.85	6	2025
Source payment records 2025-01-23 · Teva Pharmaceuticals USA, Inc. · $16.78 · Open Payments source 2025-02-06 · Teva Pharmaceuticals USA, Inc. · $19.32 · Open Payments source 2025-03-19 · Teva Pharmaceuticals USA, Inc. · $18.15 · Open Payments source 2025-04-23 · Teva Pharmaceuticals USA, Inc. · $20.42 · Open Payments source 2025-05-08 · Teva Pharmaceuticals USA, Inc. · $20.69 · Open Payments source 2025-09-04 · Teva Pharmaceuticals USA, Inc. · $18.49 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$107.15	1	2025
Source payment records 2025-04-24 · Janssen Pharmaceuticals, Inc · $107.15 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$87.29	4	2025
Source payment records 2025-03-05 · Supernus Pharmaceuticals, Inc. · $30.86 · Open Payments source 2025-04-30 · Supernus Pharmaceuticals, Inc. · $18.65 · Open Payments source 2025-08-15 · Supernus Pharmaceuticals, Inc. · $21.72 · Open Payments source 2025-10-08 · Supernus Pharmaceuticals, Inc. · $16.06 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$76.41	4	2025
Source payment records 2025-01-15 · Takeda Pharmaceuticals U.S.A., Inc. · $18.82 · Open Payments source 2025-03-06 · Takeda Pharmaceuticals U.S.A., Inc. · $26.39 · Open Payments source 2025-05-14 · Takeda Pharmaceuticals U.S.A., Inc. · $15.67 · Open Payments source 2025-12-11 · Takeda Pharmaceuticals U.S.A., Inc. · $15.53 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$70.82	4	2025
Source payment records 2025-07-10 · Vanda Pharmaceuticals Inc. · $15.43 · Open Payments source 2025-08-28 · Vanda Pharmaceuticals Inc. · $19.96 · Open Payments source 2025-10-07 · Vanda Pharmaceuticals Inc. · $18.41 · Open Payments source 2025-11-13 · Vanda Pharmaceuticals Inc. · $17.02 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$66.83	3	2025
Source payment records 2025-02-24 · Otsuka America Pharmaceutical, Inc. · $22.11 · Open Payments source 2025-04-21 · Lundbeck LLC · $21.30 · Open Payments source 2025-07-28 · Lundbeck LLC · $23.42 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$46.52	3	2025
Source payment records 2025-05-01 · Janssen Pharmaceuticals, Inc · $21.24 · Open Payments source 2025-09-25 · Janssen Pharmaceuticals, Inc · $18.07 · Open Payments source 2025-11-20 · Janssen Pharmaceuticals, Inc · $7.21 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$39.11	2	2025
Source payment records 2025-04-03 · Otsuka America Pharmaceutical, Inc. · $21.48 · Open Payments source 2025-06-02 · Otsuka America Pharmaceutical, Inc. · $17.63 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$37.58	3	2025
Source payment records 2025-01-13 · Corium, LLC · $18.83 · Open Payments source 2025-10-15 · Corium, LLC · $2.36 · Open Payments source 2025-10-15 · Corium, LLC · $16.39 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$28.50	1	2025
Source payment records 2025-07-30 · ABBVIE INC. · $28.50 · Open Payments source
RINVOQ Normalized: rinvoq	Biological	ABBVIE INC.	$23.01	1	2025
Source payment records 2025-07-25 · ABBVIE INC. · $23.01 · Open Payments source
SKYRIZI Normalized: skyrizi	Biological	ABBVIE INC.	$23.01	1	2025
Source payment records 2025-07-25 · ABBVIE INC. · $23.01 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$21.48	1	2025
Source payment records 2025-04-03 · Otsuka America Pharmaceutical, Inc. · $21.48 · Open Payments source
ZURZUVAE Normalized: zurzuvae	Drug	Sage Therapeutics, LLC	$19.37	1	2025
Source payment records 2025-06-23 · Sage Therapeutics, LLC · $19.37 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
AUSTEDO XR austedo xr	2025	Austedo Xr	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
Auvelity auvelity	2025	Auvelity	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	13 Beneficiary count suppressed	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	27 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	24 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	27	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	24	suppressed by CMS
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO XR open payments reported associated product	CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228	Austedo Xr · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Buspirone Hcl	Buspirone Hcl	94	21
Bupropion Xl	Bupropion Hcl	88	22
Trazodone Hcl	Trazodone Hcl	84	20
Aripiprazole	Aripiprazole	53	12
Lamotrigine	Lamotrigine	50	11
Clonazepam	Clonazepam	48	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	38	suppressed
Duloxetine Hcl	Duloxetine Hcl	37	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	36	suppressed
Doxepin Hcl	Doxepin Hcl	32	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	30	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	30	suppressed
Invega Sustenna	Paliperidone Palmitate	27	suppressed
Diazepam	Diazepam	24	suppressed
Sertraline Hcl	Sertraline Hcl	24	suppressed
Trintellix	Vortioxetine Hydrobromide	24	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	20	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Austedo Xr	Deutetrabenazine	15	suppressed
Gabapentin	Gabapentin	14	suppressed
Memantine Hcl	Memantine Hcl	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Ingrezza	Valbenazine Tosylate	13	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	13	suppressed
Alprazolam	Alprazolam	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Latuda	Lurasidone Hcl	12	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Risperidone	Risperidone	12	suppressed
Vilazodone Hcl	Vilazodone Hcl	12	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	11	suppressed
Lithium Carbonate	Lithium Carbonate	11	suppressed
Olanzapine	Olanzapine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$169,239.38 · 297 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, REXULTI, RINVOQ, SKYRIZI, SPRAVATO, TRINTELLIX, VRAYLAR, ZURZUVAE	6	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Austedo Xr play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error